HIV-1 inactivation by 4-vinylpyridine is enhanced by dissociating Zn(2+) from nucleocapsid protein.

HIV-1 inactivation by 4-vinylpyridine is enhanced by dissociating Zn(2+) from nucleocapsid protein. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

HIV-1 inactivation by 4-vinylpyridine is enhanced by dissociating Zn(2+) from nucleocapsid protein. Abstract Text:

Selective inactivation of critical cysteine residues in human immunodeficiency virus type one (HIV-1) was observed after treatment with 4-vinylpyridine (4-VP), with and without the membrane-permeable metal chelator N,N,N',N'-tetrakis(2-pyridylmethyl)-ethylenediamine (TPEN). Chromatographic analysis showed that cysteines contained within nucleocapsid zinc fingers, in the context of whole virus or purified protein, were essentially unreactive, but became reactive when a chelator was included. Virus treated with 4-VP showed only a modest decrease in infectivity; after TPEN addition, nearly complete inactivation of HIV-1 occurred. Similarly, quantitation of viral DNA products from 4-VP-treated virus infections showed no significant effects on reverse transcription, but did show a 14-fold reduction in proviruses; when TPEN was added, a 10(5)-fold decrease in late reverse transcription products was observed and no proviruses were detected. Since 4-VP effectiveness was greatly enhanced by TPEN, this strongly suggests that modification of nucleocapsid zinc fingers is necessary and sufficient for HIV-1 inactivation by sulfhydryl reagents.

HIV-1 inactivation by 4-vinylpyridine is enhanced by dissociating Zn(2+) from nucleocapsid protein. Publishing Authors By Initials

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

HIV-1 inactivation by 4-vinylpyridine is enhanced by dissociating Zn(2+) from nucleocapsid protein. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Virology

VOLUME: 375

Page Numbers: 148-58

Journal Abbreviation: Virology

ISSN: 0042-6822

DAY: 4

MONTH: 03

YEAR: 2008

HIV-1 inactivation by 4-vinylpyridine is enhanced by dissociating Zn(2+) from nucleocapsid protein. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 110674

HIV-1 inactivation by 4-vinylpyridine is enhanced by dissociating Zn(2+) from nucleocapsid protein. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: HIV-1 inactivation by 4-vinylpyridine is enhanced by dissociating Zn(2+) from nucleocapsid protein. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for HIV-1 inactivation by 4-vinylpyridine is enhanced by dissociating Zn(2+) from nucleocapsid protein.

AFFILIATION: AIDS Vaccine Program, Basic Research Program, SAIC-Frederick, Inc., NCI-Frederick, Building 535, 4th floor, P.O. Box B, Frederick, Maryland 21702-1201, USA.

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Virology

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

HIV-1 inactivation by 4-vinylpyridine is enhanced by dissociating Zn2+ from nucleocapsid protein Related Publications

• Chapter 63 The future of stroke prevention by risk factor modification.
• Derivation of the DIVA Score: A Clinical Prediction Rule for the Identification of Children With Difficult Intravenous Access.
• Development and physiological regulation of intestinal lipid absorption. II. Dietary lipid absorption, complex lipid synthesis, and the intracellular packaging and secretion of chylomicrons.
• Development of a German version of the knee outcome survey for daily activities.
• Diagnosis and management of vascular cognitive impairment.
• Efficiency of human immunodeficiency virus type 1 postentry infection processes: evidence against disproportionate numbers of defective virions.
• Exercise stress testing in recently abstinent chronic cocaine abusers.
• Gray matter atrophy in patients with ischemic stroke with cognitive impairment.
• HIV-1 inactivation by 4-vinylpyridine is enhanced by dissociating Zn(2+) from nucleocapsid protein.
• Hypoglycemic hemiplegia: Insulinoma masquerading as stroke.
• Life after ESPRIT: which first-line antiplatelet treatment should we use?
• Lipoprotein-associated phospholipase A2 and risk of stroke.
• Longitudinal ECG changes in cocaine users during extended abstinence.
• Longitudinal changes in white matter following ischemic stroke: a three-year follow-up study.
• Nucleocapsid protein function in early infection processes.
• Pathophysiological effects of cocaine in humans: review of scientific issues.
• Pediatric emergency department visits for diarrheal illness increased after release of undertreated sewage.
• Physiological and physiopathological effects of cocaine.
• Primary prevention of stroke: impact of healthy lifestyle.
• Processes controlling the thermal regime of saltmarsh channel beds.
• Quality of primary care and subsequent pediatric emergency department utilization.
• Racial differences in ischemic cerebrovascular disease.
• Regarding "Buprenorphine reduces alcohol drinking through activation of the nociceptin/orphanin FQ-NOP receptor system".
• Risk of psychoactive substance dependence among substance users in a trauma inpatient population.
• Screening for poor short-term outcome in acute pediatric asthma.
• Single and multiple doses of rimonabant antagonize acute effects of smoked cannabis in male cannabis users.
• Sociodemographic characteristics associated with substance use status in a trauma inpatient population.
• Species richness and the analytic geometry of latitudinal and altitudinal gradients.
• The novel protein kinase C isoforms -{delta} and -{varepsilon} modulate caerulein-induced zymogen activation in pancreatic acinar cells.
• Update on the management of hypertension to prevent stroke.